REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]).
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial).
Elevated triglycerides and atherosclerotic cardiovascular disease are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis [abstract I15].
Residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides across the cardiovascular risk spectrum [abstract].
Association of HDL subclasses with baseline coronary plaque burden by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract].
Association of inflammatory markers with baseline coronary plaque volumes by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract].
Burden of atherosclerotic cardiovascular disease risk in persons with elevated triglyceride levels according to statin use
Increased residual cardiovascular risk in US veterans and moderately-elevated baseline triglycerides and well-controlled LCL-C levels on statins
Long-term renal function worsens in high cardiovascular risk patients with high triglycerides and well-controlled low-density lipoprotein cholesterol in a real-world analysis
Icosapent ethyl (eicosapentaenoic acid ethyl ester) in statin-treated patients with elevated cardiovascular risk and very high triglyceride levels: results from the MARINE study
Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES.
Long-term statin persistence is poor among high-risk patients with baseline diabetes: a real-world administrative claims analysis
Increased cardiovascular risk in patients with diabetes, statin-controlled LDL cholesterol, and residual hypertriglyceridemia
Prevalence and predictors of residual hypertriglyceridemia according to statin use in U.S. adults with diabetes
Response by Bhatt et al to Letter Regarding Article, “REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
Risk of cardiovascular events in patients with hypertriglyceridemia: a review of real-world evidence
Prevalence Of Hypertriglyceridaemia In Statin Treated Very High-Risk Patients Who Might Benefit From Treatment With Icosapent Ethyl For Secondary Prevention In Clinical Practice–Results Of DYSIS.